Growth hormone releasing peptides
Your pituitary gland releases growth hormone in pulses, mostly at night, and that output declines with age. Growth hormone releasing peptides — sermorelin, ipamorelin, CJC-1295, tesamorelin — are studied for nudging the body's own pulses rather than replacing the hormone outright.
The articles below cover how each one works, how they differ from one another and from HGH itself, and what the research does and doesn't show. All of them are prescription-only through Promise: a licensed provider reviews every request.
88 articles on this topic
-
CJC-1295 Ipamorelin News: October 2026
The quarter brought a new WADA list, online-product notices and an evidence review. The two molecules still have different FDA records and limited human outcome data.
-
Egrifta Prescribing Information, Explained
Egrifta WR’s label covers one HIV-related use, a daily dose, four contraindications, monitoring, side effects, and product-specific storage. WR and SV directions cannot be swapped.
-
IGF-1 Levels by Age: Reading Your Lab Result
IGF-1 levels by age usually decline after early adulthood. Your lab's range puts the number in context; trial increases aren't treatment targets.
-
Sermorelin Myths: 10 Claims Checked
Sermorelin can stimulate growth-hormone release. Ten familiar claims about aging, muscle, sleep and safety go further than the human studies support.
-
1977 Nobel Prize in Medicine: Peptide Discoveries
Three scientists shared the prize for finding the brain’s hormone messages and making tiny hormone levels measurable. Here’s how that history connects to today’s prescriptions.
-
Who Discovered Ghrelin? Kojima and Kangawa
Masayasu Kojima, Kenji Kangawa and colleagues identified ghrelin in 1999. Earlier peptide and receptor discoveries set up the finding; appetite studies followed.
-
Tesamorelin Fatty Liver Trial: What It Found
A 12-month trial found less liver fat and less worsening of scarring with tesamorelin. Its 61 participants had HIV, a virus that weakens the immune system, which limits what the findings mean for everyone else.
-
10 Questions to Ask Before Starting Sermorelin
A sermorelin visit covers the goal, health history, labs, and a practical follow-up plan. These ten questions explain why each part matters and what a clear answer includes.
-
CJC-1295 FDA Status: Nominations, Review and Votes
CJC-1295 is not FDA-approved; a compounded prescription is different from an FDA-approved product. Here is what its nominations and votes mean today.
-
13 Questions to Ask Before Tesamorelin
A tesamorelin review turns on a short list: what you want it for, your cancer, pregnancy and pituitary history, and your blood sugar and IGF-1. Here are the questions worth bringing, and the label line or trial finding behind each.
-
Sermorelin Allergic Reaction: What Reports Mean
New reporting describes severe reactions after peptide injections. Five accounts cannot establish a risk rate; breathing trouble or collapse means emergency care.
-
Should I Take Sermorelin? How a Provider Decides
Should I take sermorelin? It may be worth discussing for a clear, measurable goal, but a provider first checks the thyroid, cancer history, blood sugar, other medicines and whether you're tested in sport.
-
Sermorelin for Sleep: What the Research Shows
The link between growth hormone and deep sleep is real. The evidence that sermorelin improves sleep is not: the one trial that tested it found slightly worse sleep scores.
-
12 Questions to Ask About Peptide Therapy
Twelve questions worth bringing to a peptide visit, grouped by what they uncover: the evidence, the review status, your own health and the vial itself, with why each is asked and what a straight answer sounds like.
-
Tesamorelin News Update: September 2026
A quiet quarter for the medicine itself: Egrifta's label and its narrow use did not change. The news came from around it, in FDA's letters to online sellers, WADA's 2027 list and three new papers.
-
Sermorelin News Update: September 2026
This quarter was quiet: no new human trial changed the evidence, and July’s FDA compounding panel did not review sermorelin. The useful update is what has not changed—and which FDA list actually applies.
-
Tesamorelin Clinical Trials: What the Studies Show
The large trials found less visceral abdominal fat in adults with HIV-associated lipodystrophy. They did not test general weight loss, anti-aging, or the compounded formulations sold today.
-
Who Discovered GHRH? The Two 1982 Teams
Two independent teams identified GHRH in 1982, using an unexpected clue from pancreatic tumors. Their papers opened the path to sermorelin, tesamorelin and CJC-1295.
-
Hims Peptides: What Hims & Hers Plans to Sell
Hims & Hers says a peptide and wellness category is coming, but the rollout is phased. Some offerings are planned for 2026, while BPC-157 depends on unfinished FDA rulemaking.
-
Sermorelin Clinical Trials: What the Studies Show
The 11-man study is real. Its results are narrower than the sales pitch, and later studies add evidence without settling the big claims.
Page 1 of 5 · 88 articles